![]() ![]() Its industry sports an average Forward P/E of 24.52, so we one might conclude that Bio-Rad Laboratories is trading at a premium comparatively. Investors should also note Bio-Rad Laboratories's current valuation metrics, including its Forward P/E ratio of 25.95. Bio-Rad Laboratories currently has a Zacks Rank of #4 (Sell). Within the past 30 days, our consensus EPS projection remained stagnant. ![]() Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Our system takes these estimate changes into account and delivers a clear, actionable rating model. We developed the Zacks Rank to capitalize on this phenomenon. Our research shows that these estimate changes are directly correlated with near-term stock prices. BIO is currently trading in the 20-30 percentile range relative to its historical Stock Score levels. The Score for BIO is 22, which is 56 below its historic median score of 50, and infers higher risk than normal. ![]() With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. The current Bio-Rad Laboratories BIO share price is 365.54. Recent revisions tend to reflect the latest near-term business trends. These totals would mark changes of -2.08% and +3.8%, respectively, from last year.Īny recent changes to analyst estimates for Bio-Rad Laboratories should also be noted by investors. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $14.12 per share and revenue of $2.91 billion. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $696.05 million, up 0.72% from the year-ago period. The company is expected to report EPS of $2.90, down 14.2% from the prior-year quarter. Investors will be hoping for strength from Bio-Rad Laboratories as it approaches its next earnings release. In that same time, the Medical sector gained 0.08%, while the S&P 500 gained 4.31%. At the same time, the Dow lost 0.01%, and the tech-heavy Nasdaq lost 1.26%.Ĭoming into today, shares of the maker of instruments used in biomedical research had lost 1.95% in the past month. Consequently, Bio Rad develops and markets now diagnostic tests and systems for medical analysis laboratories, blood transfusion centres and industrial. This change lagged the S&P 500's 0.37% gain on the day. Bio-Rad Laboratories (BIO) closed at $364.78 in the latest trading session, marking a -0.46% move from the prior day. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |